Sources and References

• Rieder, T. (2020). “Solving the Opioid Crisis Isn’t Just a Public Health Challenge – It’s a Bioethics Challenge.” Hastings Center Report 50(4), 24–32.
• Earp, B., Lewis, J., Hart, C. et al. (2021). “Racial Justice Requires Ending the War on Drugs.” American Journal of Bioethics 21(4), 4–19.
• Husak, D. (1989). “Recreational Drugs and Paternalism.” Law and Philosophy 8, 353–381.
• de Marneffe, P. (2006). “Avoiding Paternalism.” Philosophy and Public Affairs 34, 68–94.
• Stoljar, N. (2020). “Disgust or Dignity? The Moral Basis of Harm Reduction.” Health Care Analysis 28, 343–351.
• King, N. (2020). “Harm Reduction: A Misnomer.” Health Care Analysis 28, 324–334.
• Rieder, T. (2021). “Solving the War on Drugs Requires Decriminalization. Does It Require Legalization?” American Journal of Bioethics 21, 38–41.
• de Marneffe, P. (2013). “Vice Laws and Self-Sovereignty.” Criminal Law and Philosophy 7, 29–41.
• Leshner, A. (1997). “Addiction Is a Brain Disease, and It Matters.” Science 278(5335), 46–48.
• Pickard, H. (2018). “The Puzzle of Addiction.” In H. Pickard & S. Ahmed (Eds.), Routledge Handbook of Philosophy of Science and Addiction, pp. 9–22.
• Hart, C. (2017a). “Viewing Addiction as a Brain Disease Promotes Social Injustice.” Nature Human Behaviour 1, 0055.
• Bedi, G. et al. (2017). “Addiction as a Brain Disease Does Not Promote Social Injustice.” Nature Human Behaviour.
• Hart, C. (2017b). “Reply to ‘Addiction as a Brain Disease Does Not Promote Social Injustice’.” Nature Human Behaviour.
• Husak, D. (2000). “Liberal Neutrality, Autonomy, and Drug Prohibitions.” Philosophy and Public Affairs 29, 43–80.
• Levy, N. (2006). “Autonomy and Addiction.” Canadian Journal of Philosophy 36(3), 427–447.
• Charland, L. (2020). “A Puzzling Anomaly: Decision-Making Capacity and Research on Addiction.” In A. Iltis & D. Mackay (Eds.), Oxford Handbook on Research Ethics. Oxford University Press.
• Steel, D., Marchand, K., & Oviedo-Joekes, E. (2017). “Our Life Depends on This Drug: Competence, Inequity, and Voluntary Consent in Clinical Trials on Supervised Injectable Opioid Assisted Treatment.” American Journal of Bioethics 17(12), 32–40.
• Charland, L. (2018). “Competence and Inequity Are Both Important to the Ethics of Supervised Opioid Assisted Treatment.” American Journal of Bioethics 17(12), 41–43.
• Morse, S. (2013). “A Good Enough Reason: Addiction, Agency, and Criminal Responsibility.” Inquiry 56, 490–518.
• Kennett, J., Vincent, N., & Snoek, A. (2015). “Drug Addiction and Criminal Responsibility.” In J. Clausen & N. Levy (Eds.), Handbook of Neuroethics, pp. 1065–1083. Springer.
• Bayer, R. (2008). “Stigma and the Ethics of Public Health: Not Can We but Should We?” Social Science and Medicine 67, 463–472.
• Bell, K. et al. (2010). “Smoking, Stigma, and Tobacco ‘Denormalization’: Further Reflections on Stigma as a Public Health Tool.” Social Science and Medicine 70, 295–299.
• Room, R. (2005). “Stigma, Social Inequality, and Alcohol and Drug Use.” Drug and Alcohol Review 24, 143–155.

Chapter 1: The War on Drugs – History and Ethical Dimensions

1.1 A Brief History of Drug Prohibition

The so-called War on Drugs (禁毒战争) has shaped the landscape of drug policy in North America and beyond for over half a century. In June 1971, U.S. President Richard Nixon declared drug abuse “public enemy number one,” dramatically expanding federal funding for drug-control agencies. What began as a relatively modest enforcement initiative grew, under President Ronald Reagan in the 1980s, into a sweeping campaign of criminal punishment that prioritized incarceration over treatment. The number of Americans incarcerated for nonviolent drug offenses rose from roughly 50,000 in 1980 to 400,000 by 1997.

In Canada, while the criminal justice approach was not identical to that of the United States, a parallel prohibitionist orientation prevailed through the Controlled Drugs and Substances Act and its predecessors. Drug policy on both sides of the border has historically treated drug use as primarily a law-enforcement problem rather than a matter of public health.

1.1.1 The Ethical Stakes

Travis Rieder (2020) argues that the opioid crisis is not merely a public health challenge but a bioethics (生命伦理学) challenge. The crisis reveals deep tensions between competing values: the imperative to reduce suffering, the importance of personal liberty, the demands of justice, and the role of the state in regulating substances that carry both enormous risks and genuine medical benefits. Opioids are among the most powerful analgesics available, yet in 2021 alone nearly 8,000 Canadians died of opioid overdoses. Navigating between the therapeutic value and the lethal risks of these substances requires ethical reasoning, not just epidemiological data.

1.2 Racial Injustice and Drug Policy

1.2.1 Earp, Lewis, and Hart on Racial Justice

Earp, Lewis, Hart et al. (2021) mount a forceful argument that racial justice (种族正义) requires ending the War on Drugs. Their central thesis rests on several interconnected claims:

1. Historical racism in drug law. Drug criminalization has been rooted in explicit racism from its inception. Early twentieth-century drug laws in the United States targeted Chinese immigrants (opium), Mexican Americans (cannabis), and Black Americans (cocaine) through racialized moral panics.

2. Ongoing disparate enforcement. Despite comparable rates of drug use across racial groups, Black and Latino communities are disproportionately subject to arrest, prosecution, and incarceration. Following the passage of the Anti-Drug Abuse Act of 1986, which established a 100:1 sentencing disparity between crack and powder cocaine, the Black incarceration rate in America rose from approximately 600 per 100,000 in 1970 to 1,808 per 100,000 in 2000.

3. Structural harms of prohibition. Criminalization undermines harm-reduction programs, increases disease transmission, reduces life expectancy through incarceration, and destabilizes families and communities.

1.2.2 A Four-Part Reform Strategy

Earp et al. propose four interrelated reforms:

• Decriminalization (除罪化) of all psychoactive substances for personal use
• Expungement of criminal convictions for nonviolent drug offenses and release of those currently incarcerated for such offenses
• Legalization (合法化) and careful regulation of currently illicit drugs
• Community-building initiatives and expanded harm-reduction programs directed at affected communities

Chapter 2: The Opioid Crisis and Racial Justice

2.1 The Opioid Crisis as an Ethical Crisis

The contemporary opioid crisis began in the late 1990s, when pharmaceutical companies aggressively marketed opioid painkillers – most notoriously OxyContin – as safe and minimally addictive. Physicians, acting on this misleading information, prescribed opioids at unprecedented rates. When regulatory and legal pressure reduced the supply of prescription opioids, many patients turned to illicit alternatives such as heroin and illicitly manufactured fentanyl. The result has been a catastrophic wave of overdose deaths.

Rieder emphasizes that the crisis implicates multiple ethical domains: the responsibilities of pharmaceutical companies, the duties of prescribing physicians, the adequacy of regulatory oversight, and the justice of policy responses. A purely medical or epidemiological approach cannot capture these normative dimensions.

2.2 Race and the Opioid Crisis

2.2.1 The “Sympathetic Victim” Problem

A troubling pattern emerged in public discourse around the opioid crisis. When opioid addiction was perceived as affecting primarily white, suburban, and rural communities, the policy response shifted markedly toward treatment and compassion – a stark contrast to the punitive response that characterized the crack cocaine epidemic of the 1980s and 1990s, which disproportionately affected Black communities.

Earp et al. argue that this double standard reveals the racial logic embedded in drug policy. The harms of the War on Drugs were never simply a matter of policy failure; they reflected, and continue to reflect, structural racism.

2.2.2 Toward Racially Just Drug Policy

A racially just drug policy, according to Earp and colleagues, must address both the immediate harms of criminalization and the historical injustices it has produced. This requires not only policy reform but also reparative measures: expungement of records, community investment, and an explicit reckoning with the racist origins and outcomes of prohibition.

Chapter 3: Paternalism – When May the State Restrict Drug Use?

3.1 The Concept of Paternalism

Paternalism (家长主义) refers to the interference with a person’s liberty or autonomy, against their will, justified or motivated by the claim that the person interfered with will be better off or protected from harm. In the context of drug policy, the central question is: may the state legitimately prohibit individuals from using drugs for their own protection?

This question lies at the heart of liberal political philosophy. John Stuart Mill’s harm principle (密尔的伤害原则) holds that the only legitimate reason for restricting individual liberty is to prevent harm to others. On this view, purely self-regarding drug use – use that harms no one but the user – cannot be legitimately prohibited. Legal paternalism (法律家长主义), by contrast, holds that the state may sometimes restrict liberty for the person’s own good.

3.2 Husak on Recreational Drugs and Paternalism

3.2.1 The Core Argument

Douglas Husak (1989) argues that the paternalistic arguments typically offered in defense of criminalizing recreational drug use rest on empirically contentious and often unsupported assumptions. His central claims include:

1. The role of illegality in harm. Much of the harm attributed to recreational drugs is actually a product of their illegality – contaminated supply, dangerous purchasing environments, lack of quality control, and the violence associated with black markets. A fair assessment of drug harms must distinguish between harms intrinsic to the substances and harms produced by the legal regime.

2. Inconsistency in treatment. Paternalistic arguments for drug prohibition face a serious consistency problem. Alcohol and tobacco cause more death and disease than most illicit drugs, yet they are legal. A principled paternalist must explain why some drugs warrant criminal prohibition while others do not.

3. Respect for rational adults. Husak argues that the criminal justice system should tolerate the use of recreational drugs among rational adults. Paternalism that extends to criminalizing the choices of competent adults is difficult to reconcile with the values of a liberal democratic state.

3.2.2 The Limits of Justified Paternalism

Husak does not reject all forms of paternalism. He accepts that some paternalistic interventions can be justified – for example, seatbelt laws or restrictions on dangerous consumer products. His argument is that the specific case for criminalizing recreational drug use fails to meet the standards that justified paternalism requires: clear evidence of serious harm, proportionality of response, and respect for the autonomy of competent agents.

3.3 De Marneffe on Avoiding Paternalism

3.3.1 The Non-Paternalistic Case for Regulation

Peter de Marneffe (2006) takes a different approach. Rather than defending drug prohibition on paternalistic grounds, he explores whether non-paternalistic arguments might justify certain drug regulations. De Marneffe is sensitive to the charge that drug laws are paternalistic and seeks to identify when a policy that protects people from their own choices might nonetheless be justified on grounds other than the individual’s own good.

3.3.2 Key Distinctions

De Marneffe draws an important distinction between:

• Paternalistic justification: A policy is paternalistic if it restricts liberty for the sake of the person whose liberty is restricted.
• Non-paternalistic justification: A policy might restrict liberty to protect third parties (e.g., the families and dependents of drug users) or to promote public goods (e.g., public health, social stability).

He argues that if the benefits of drug prohibition to potential drug users are too small to justify the policy, the policy is not paternalistic even if it is adopted with the aim of protecting potential users who do not want to be protected. This opens space for arguments that certain drug regulations can be justified without appealing to paternalism – for example, by appealing to the harms that drug abuse imposes on others.

3.3.3 Rights and Constraints

De Marneffe also addresses the role of rights (权利) in constraining government policy. Certain basic liberties – freedom of thought, expression, and association – should not be limited for paternalistic reasons. But not all liberties carry the same weight. The question is whether recreational drug use is the kind of activity that falls within the sphere of protected basic liberties or whether it is more analogous to activities (like driving without a license) that the state may regulate for the common good.

Chapter 4: Harm Reduction – Philosophical Foundations

4.1 What Is Harm Reduction?

Harm reduction (减害) is an approach to drug policy that prioritizes reducing the negative consequences of drug use rather than eliminating drug use itself. Practical harm-reduction interventions include needle exchange programs, supervised injection sites, naloxone distribution, drug checking services, and opioid substitution therapy (e.g., methadone or buprenorphine).

The philosophical significance of harm reduction lies in its departure from the abstinence model (戒断模式), which treats the cessation of drug use as the sole legitimate goal of drug policy. Harm reduction accepts that some people will continue to use drugs and asks how policy can minimize the harms associated with that use.

4.2 Stoljar on Dignity as the Moral Basis of Harm Reduction

4.2.1 Beyond Consequentialism

Natalie Stoljar (2020) challenges the common assumption that harm reduction is justified on purely consequentialist (后果主义的) grounds – that is, because it produces better health outcomes than abstinence-only approaches. While the consequentialist case is strong, Stoljar argues that it is incomplete.

The moral justification of harm reduction is usually presumed to be consequentialist because the goal of harm reduction is to reduce the harmful health consequences of risky behaviors. However, because harm reduction is associated with a consequentialist justification and the abstinence model is associated with a deontological (义务论的) justification grounded in the duty not to use drugs, the potential for a deontological justification of harm reduction has been overlooked.

4.2.2 Autonomy and Dignity

Stoljar’s central contribution is to argue that the moral duty to protect autonomy (自主性) and dignity (尊严) – duties that have been recognized in other areas of medical ethics – also justifies harm reduction as a public health policy. People who use drugs retain their dignity as persons, and policies that treat them as moral agents worthy of respect are not merely pragmatic concessions but expressions of a fundamental ethical commitment.

4.3 King on Harm Reduction as a “Misnomer”

4.3.1 Against Utilitarian Framing

Nicholas King (2020) argues that the term “harm reduction” is itself a misnomer (用词不当) that obscures the true moral foundations of harm-reduction practice. His argument proceeds in three stages:

1. Historical genesis. The origins of harm-reduction programs were not utilitarian but arose from a commitment to helping the most vulnerable and marginalized members of society.

2. Practical implementation. The practical implementation of harm reduction is not, and probably cannot be, purely utilitarian. Harm-reduction workers are motivated by solidarity with and compassion for people who use drugs, not by aggregate welfare calculations.

3. Consequentialist framing causes harm. Continued utilitarian justification is untenable and may itself cause harm by subjecting the lives of vulnerable people to a cost-benefit calculus that can be used to withdraw services when they are deemed insufficiently “cost-effective.”

4.3.2 A Prioritarian Alternative

King contends that the rightness of harm-reduction programs has nothing to do with harm and nothing to do with reduction, but rather inheres in:

• Rejecting Manichaeanism – the division of people into morally pure and morally corrupt categories
• Rejecting moral desert (道德应得) – the idea that people who use drugs deserve their suffering
• Respecting and giving priority to the lives of the worst off (最弱势群体)

This amounts to a prioritarian (优先主义的) rather than a utilitarian justification: we should help people who use drugs because they are among the most vulnerable members of society, and justice requires that we give priority to the needs of the worst off.

Chapter 5: Decriminalization vs. Legalization

5.1 Conceptual Distinctions

The debate over drug policy reform involves several distinct proposals that are often conflated:

• Decriminalization (除罪化): Removing criminal penalties for drug use and personal possession, while retaining civil penalties (e.g., fines) or regulatory oversight. Drug production and distribution may remain criminal offenses.
• Legalization (合法化): Making drug use, possession, and potentially production and sale legal, subject to regulation (similar to alcohol or tobacco).
• Prohibition (禁止): Maintaining criminal penalties for use, possession, production, and distribution.

5.2 Rieder on Decriminalization and Legalization

5.2.1 The Case for Decriminalization

Travis Rieder (2021) argues that ending the War on Drugs requires, at minimum, decriminalization of drug use and possession. The case for decriminalization rests on multiple grounds:

• The criminal justice approach has failed to reduce drug use or drug-related harm.
• Criminalization causes massive collateral harm: incarceration, criminal records, family disruption, and racial injustice.
• Treating drug use as a public health matter rather than a criminal matter is both more humane and more effective.

5.2.2 The Challenge of Legalization

However, Rieder is more cautious about full legalization. He argues that increased access to badly regulated drugs poses a serious challenge to the argument for legalization, especially if legalization implies that all drugs should be accessible to anyone over a certain age. The risks include:

• Corporate exploitation. As the history of the tobacco and alcohol industries demonstrates, legal drug markets can be captured by profit-driven corporations that have incentives to maximize consumption, including among vulnerable populations.
• Regulatory challenges. The regulatory frameworks needed to ensure safe legal drug markets are complex and may be difficult to implement effectively.
• Uncertain consequences. The effects of full legalization on rates of drug use and addiction are difficult to predict.

Rieder supports a carefully regulated safe-supply (安全供给) policy that balances the risks and benefits of access to drugs, but stops short of endorsing unrestricted legalization.

5.3 De Marneffe on Vice Laws and Self-Sovereignty

5.3.1 The Right of Self-Sovereignty

Peter de Marneffe (2013) introduces the concept of self-sovereignty (自我主权) to navigate the space between criminalization and legalization. Self-sovereignty is the right of individuals to control their own minds and bodies. De Marneffe argues:

1. Criminalization violates self-sovereignty. Laws that criminalize drug use and possession – subjecting individuals to arrest, prosecution, and imprisonment – violate the right of self-sovereignty by depriving individuals of important forms of control over their own minds and bodies.

2. Non-legalization does not violate self-sovereignty. However, the state’s decision not to create a legal market for certain drugs – that is, to maintain their illegality without criminalizing users – does not violate this right. There is a moral difference between punishing someone for what they put in their own body and declining to create commercial infrastructure for the sale of dangerous substances.

3. Consistency of decriminalization without legalization. It is therefore consistent, as a matter of principle, to advocate decriminalization while opposing legalization.

Chapter 6: Is Addiction a Brain Disease?

6.1 The Brain Disease Model of Addiction

6.1.1 Leshner’s Foundational Argument

In a landmark 1997 article in Science, Alan Leshner, then director of the U.S. National Institute on Drug Abuse (NIDA), argued that addiction is a brain disease (成瘾是一种脑部疾病). Leshner’s central claims were:

1. Neurobiological evidence. Prolonged drug use produces measurable changes in brain structure and function, particularly in the reward and motivation circuitry involving dopamine pathways.

2. The hijacking metaphor. Drugs “hijack” the brain’s motivational and reward systems, transforming voluntary drug use into compulsive use. The transition from voluntary to compulsive use marks the onset of disease.

3. Policy implications. Recognizing addiction as a brain disease should reduce stigma, increase funding for research and treatment, and shift policy away from punishment and toward medical intervention.

6.1.2 The Promise of the BDMA

The brain disease model was intended to have several beneficial effects: reducing moral stigma by reframing addiction as a medical condition rather than a moral failing; securing funding for neuroscience research; and promoting evidence-based treatment. To the extent that it has achieved these goals, the model has been a force for good.

6.2 Critiques of the Brain Disease Model

6.2.1 Hart: Brain Disease and Social Injustice

Carl Hart (2017a) offers a powerful critique of the brain disease model, arguing that it promotes social injustice (社会不公). His key arguments include:

1. Weak empirical support. Hart contends that there are virtually no data showing that addiction is a disease of the brain in the way that Huntington’s disease or Parkinson’s disease are. We cannot reliably distinguish the brains of addicted persons from those of non-addicted persons using neuroimaging.

2. Ignoring social determinants. If the problem is framed as an interaction between a drug and an individual brain, then solutions will focus on removing drugs from society (through law enforcement) or fixing individual brains (through pharmacology). There is no need to understand or address the socioeconomic factors (社会经济因素) – poverty, racism, lack of opportunity – that drive and maintain addiction.

3. Majority do not become addicted. The vast majority of people who use drugs, including drugs like heroin and cocaine, never become addicted. For those who do, co-occurring psychiatric disorders and socioeconomic factors account for a substantial proportion of cases.

4. Reinforcing punitive approaches. By focusing on the drug-brain interaction, the brain disease model inadvertently supports enforcement-based approaches: if drugs are the problem, remove them; if brains are the problem, treat them. Neither framing addresses the structural conditions that produce and sustain addiction.

6.2.2 Bedi et al.: A Defense of the BDMA

Bedi et al. (2017) respond to Hart by arguing that the brain disease model does not inherently promote social injustice. They contend that recognizing the neurobiological dimensions of addiction is compatible with – and indeed should inform – attention to social determinants. The brain disease model and social justice concerns are not mutually exclusive.

Hart (2017b) replies that while the two are logically compatible, the practical effect of the brain disease model has been to divert attention and resources away from social determinants and toward biomedical approaches, with unjust consequences for marginalized communities.

6.3 Pickard: The Puzzle of Addiction

6.3.1 What the Puzzle Is

Hanna Pickard (2018) reframes the question by identifying the core puzzle of addiction (成瘾之谜): why do people continue to use drugs when the costs manifestly outweigh the benefits? This shift in framing is important because it does not presuppose any particular model of addiction (brain disease, moral failing, rational choice) but instead asks what any adequate theory must explain.

6.3.2 Against the Compulsion Model

The traditional explanation appeals to compulsion (强迫性): addicts use drugs because they cannot help it; their cravings are irresistible. Pickard marshals evidence against this view:

• Drug use is responsive to incentives (激励). Laboratory studies show that people with addictions will choose alternatives to drugs when sufficiently attractive alternatives are available.
• People with addictions routinely make choices about when, where, and how much to use. This is inconsistent with the idea that drug use is straightforwardly compulsive.
• If cravings were truly irresistible, this would provide a generic excuse for all behavior associated with addiction, but this does not match our considered moral judgments.

6.3.3 Solving the Puzzle

Pickard identifies at least five factors that contribute to continued drug use despite its costs:

1. Temporal discounting (时间折扣): Overvaluing immediate rewards relative to future costs.
2. Denial (否认): Failing to acknowledge or recognize the extent of the costs.
3. Habit (习惯): Drug use becomes deeply habituated, requiring active concentration to resist.
4. Psychological factors: Including self-harm, negative self-concept, and coping with trauma or distress.
5. Strong and persistent desire: Craving is powerful even if not literally irresistible.

Chapter 7: Addiction, Autonomy, and Moral Agency

7.1 Autonomy and Drug Prohibition

7.1.1 Husak on Liberal Neutrality

Douglas Husak (2000) argues that members of liberal states (自由主义国家), which accept the principle of liberal neutrality (自由主义中立性) between different conceptions of the good life, must find the criminalization of drug use unacceptable. His argument proceeds as follows:

1. Liberal neutrality. The state should be neutral with respect to reasonable conceptions of the good life. This is a foundational commitment of liberal political philosophy, grounded in respect for personal autonomy (自主性).

2. Drug use and the good life. Some reasonable conceptions of the good life include the recreational use of drugs – for pleasure, for creativity, for social bonding, for spiritual exploration. If the state is to remain neutral, it cannot single out drug use for criminal prohibition merely because some people disapprove of it.

3. The autonomy objection. One might argue that drug use undermines autonomy and that the state may therefore prohibit it in order to protect the conditions of autonomous agency. Husak considers this objection seriously, examining accounts of autonomy such as Joseph Raz’s, which treats autonomy as a capacity that can be promoted or undermined by social conditions.

4. Response. Husak contends that while drug addiction can impair autonomy, the same is true of many legal activities (excessive work, unhealthy eating, compulsive gambling). The selective criminalization of drug use cannot be justified by appeal to autonomy unless one is prepared to criminalize a wide range of other autonomy-impairing activities – which no liberal state does.

7.1.2 Tentative Conclusion

Husak makes the tentative claim that drug use should be permitted on the basis of liberal neutrality, while acknowledging that he has not conclusively disproven the possibility of a neutral rationale for prohibition. The burden of proof, however, rests with those who would restrict liberty.

7.2 Levy on Autonomy and Addiction

7.2.1 The Problem of Extended Agency

Neil Levy (2006) argues that while addiction is universally recognized as impairing autonomy, philosophers have frequently misunderstood the nature of this impairment. Standard accounts of autonomy (自主性) – whether hierarchical (Frankfurt), reasons-responsive (Fischer and Ravizza), or proceduralist (Dworkin) – struggle to explain how addiction undermines autonomy, because people with addictions often do what they want, endorse their desires upon reflection, and respond to reasons.

7.2.2 Autonomy as Extended Agency

Levy proposes that autonomy consists essentially in the exercise of the capacity for extended agency (延展性行动能力) – the ability to integrate one’s life over time, to pursue a coherent conception of the good, and to make one’s present choices cohere with one’s long-term plans and values.

Addiction impairs autonomy because it undermines extended agency. The person with an addiction experiences a fractured personality (分裂的人格): they do what they want in the moment, but they also do what they do not want when viewed from the perspective of their life as a whole. The addict both wants and does not want to use drugs, depending on which temporal perspective is adopted.

7.2.3 Implications for Policy

If Levy is correct, then the autonomy-based case for drug prohibition is more complex than it initially appears. Prohibition might protect extended agency by removing a source of disruption, but it might also undermine extended agency by criminalizing a choice that some people make as part of a coherent life plan. The relationship between drug policy and autonomy is not straightforward.

Chapter 8: Research Ethics and Addiction

8.1 The Problem of Decision-Making Capacity

8.1.1 Charland on a Puzzling Anomaly

Louis Charland (2020) identifies a striking gap in the ethics of addiction research: there is a puzzling lack of clinical research on decision-making capacity (决策能力) in people with severe addiction, even though such research is extensive in other areas of bioethics (e.g., dementia, mental illness).

Charland’s central arguments are:

1. Addiction may impair capacity. Severe addiction plausibly impairs the cognitive and volitional capacities required for informed consent (知情同意). The cyclical nature of addiction – with periods of intense craving, intoxication, and withdrawal – raises questions about whether participants in addiction research can give genuinely voluntary and competent consent.

2. The drug dealer’s perspective. Charland provocatively observes that drug dealers understand and exploit the impaired decision-making capacity of their clients. If dealers recognize that addiction compromises judgment, it is puzzling that the research ethics community has not subjected this question to more rigorous investigation.

3. A possible double standard. There appears to be an ethical double standard: society treats people with addiction as lacking competence in some contexts (e.g., criminal law, where addiction may be offered as a mitigating factor) while assuming full competence in others (e.g., research ethics, where participants must give informed consent).

8.2 Steel, Marchand, and Oviedo-Joekes on Consent and Inequity

8.2.1 Supervised Injectable Opioid Assisted Treatment

Steel, Marchand, and Oviedo-Joekes (2017) examine the ethics of supervised injectable opioid assisted treatment (siOAT) (监督式注射阿片类辅助治疗), a medical intervention that prescribes injectable opioids to individuals for whom other forms of treatment have been ineffective. Clinical trials of siOAT raise acute questions about consent, because participants are opioid-dependent and may perceive the treatment as their only option.

8.2.2 Reframing the Problem

The authors argue against the assumption that opioid-dependent individuals should be presumed incompetent (无能力的) to consent to research on siOAT. While concerns about competence and voluntary consent deserve careful attention, framing the issue solely as a matter of individual competence ignores a more fundamental problem: inequity (不公平) in access to treatment.

If siOAT is an effective medical treatment, then the ethical problem is not that research participants may lack the capacity to consent, but that they face an unjust choice: participate in research or go without treatment. The solution is not to restrict research participation but to expand access to treatment.

8.3 Charland on Competence and Inequity

8.3.1 Both Dimensions Matter

In his 2018 commentary on Steel et al., Charland agrees that inequity is a central concern but maintains that questions of competence (能力) remain independently important. Even if we address inequity in access to treatment, we must still ask whether severe addiction impairs the cognitive capacities required for valid consent. These are not competing concerns but complementary ones.

Charland argues that it is possible to make a choice without being in control – to make decisions without having full decision-making capacity. This distinction is crucial for research ethics: the mere fact that a person expresses a preference or signs a consent form does not guarantee that they have the capacity for genuinely informed and voluntary consent.

Chapter 9: Criminal Responsibility and Addiction

9.1 The Legal Framework

The question of criminal responsibility (刑事责任) in the context of addiction concerns whether, and to what extent, addiction should serve as an excuse or mitigating factor in criminal law. The standard conditions for criminal responsibility are:

• Actus reus (犯罪行为): The defendant performed a voluntary act.
• Mens rea (犯罪意图): The defendant had the requisite mental state (intention, knowledge, recklessness, etc.).

Defenses that negate responsibility typically show that one of these conditions was not met – for example, that the defendant acted under compulsion (强迫), duress (胁迫), or insanity (精神错乱).

9.2 Morse on Addiction and Criminal Responsibility

9.2.1 The Core Position

Stephen Morse (2013) argues that most people with addictions retain sufficient rational capacity (理性能力) and control capacity (控制能力) to be held criminally responsible, at least for crimes that are not part of the definition of addiction itself (i.e., crimes other than drug purchase and possession for personal use).

His key arguments include:

1. Folk psychological criteria. The criteria for criminal responsibility are folk psychological (民间心理学的) – they concern beliefs, desires, intentions, and capacities for practical reasoning. Scientific information about brain changes in addiction must be “translated” into these folk psychological terms before it can bear on questions of legal responsibility.

2. Addiction is not compulsion. Addiction does not typically render conduct involuntary or compulsive in the legally relevant sense. People with addictions make choices, respond to incentives, and exercise practical reasoning, even if these capacities are impaired.

3. Purchase and possession as exceptions. Morse acknowledges that there is good reason to excuse or mitigate criminal liability for the crimes of drug purchase and possession for personal use, since these acts are closely tied to the condition of addiction itself.

4. No automatic excuse. The label “disease” or “brain disease” does not automatically excuse conduct. Addicts must independently be shown not to meet responsibility criteria; the disease label alone is insufficient.

9.3 Kennett, Vincent, and Snoek on Addiction and Responsibility

9.3.1 A More Nuanced Position

Kennett, Vincent, and Snoek (2015) challenge Morse’s position by arguing for a more differentiated assessment. Their central claims:

1. Some addicted persons meet criteria for excusal. A subgroup of people with addictions does meet plausible criteria for compulsion (强迫性), coercion (胁迫), or irrationality (非理性). The severity and character of addiction vary widely, and a one-size-fits-all approach to responsibility is inappropriate.

2. Responsibility for becoming addicted. Morse argues that people are responsible for becoming addicted. Kennett et al. respond that few people are fully responsible for the onset of addiction. Many begin using drugs as adolescents, under conditions of social disadvantage, trauma, or mental illness. The assumption of full responsibility for becoming addicted is unrealistic for a large proportion of the addicted population.

3. Failure to manage addiction. Some people with addictions can be at least partly excused for failing to manage their addiction. The resources – financial, social, psychological – required for successful recovery are not equally available to all, and holding people responsible for failing to recover when recovery resources are systematically denied to them is unjust.

9.3.2 Degrees of Responsibility

Kennett et al. propose a graduated approach to criminal responsibility in addiction, one that recognizes degrees of impairment and degrees of culpability. Rather than asking the binary question “Is this person responsible or not?”, we should ask “To what extent is this person’s agency impaired, and what resources did they have available for managing their condition?”

Chapter 10: Stigma and Public Health – The Case of Tobacco Control

10.1 Stigma as a Public Health Tool

10.1.1 Bayer on Stigma and Tobacco

Ronald Bayer (2008) raises a provocative question: not can we but should we use stigma (污名化) as a tool of public health? His argument draws on the contrasting history of two public health crises:

• HIV/AIDS: The public health response to HIV/AIDS was built on the principle that stigmatization is counterproductive. People who are stigmatized avoid testing, treatment, and disclosure. The anti-stigma approach became a core tenet of public health ethics.

• Tobacco: The public health response to smoking took a markedly different path. Denormalization campaigns explicitly sought to make smoking socially unacceptable – to marginalize and stigmatize smoking behavior. These campaigns were associated with dramatic declines in smoking rates.

Bayer argues that the mobilization of stigma may effectively reduce the prevalence of smoking and is therefore not necessarily antithetical to public health goals. The ethical question is whether the deliberate use of stigma can be justified, given its potential to cause psychological harm and social exclusion.

10.1.2 Bell et al. on Denormalization

Bell et al. (2010) offer a critical response, arguing that stigmatizing smoking may not ultimately reduce smoking prevalence among the most disadvantaged smokers and is likely to exacerbate health inequalities (健康不平等). Their concerns include:

• Stigmatization may deter disadvantaged smokers from seeking help, thereby worsening rather than improving health outcomes.
• The burdens of stigma fall disproportionately on those who are already marginalized – low-income individuals, people with mental health conditions, and members of racialized communities.
• Denormalization strategies risk conflating the behavior (smoking) with the person (the smoker), leading to discrimination and social exclusion.

10.2 Stigma, Inequality, and Drug Use

10.2.1 Room on Stigma and Social Inequality

Robin Room (2005) situates the discussion of stigma in the broader context of social inequality (社会不平等). Stigma related to alcohol and drug use is not a neutral public health instrument; it reflects and reinforces existing social hierarchies. Those at the bottom of the social ladder are most likely to be stigmatized for their substance use and least likely to have the resources to resist or escape that stigma.

10.2.2 Williamson et al. on Stigma and Citizen Involvement

Williamson et al. (2014) further explore the implications of using stigma as a public health tool, arguing that stigmatization undermines the civic participation and democratic voice of stigmatized groups. When people who use drugs are stigmatized, they are less likely to participate in policy discussions, advocate for their own interests, or hold institutions accountable – precisely the forms of civic engagement that democratic societies depend upon.

10.3 Ethical Frameworks for Evaluating Stigma

The debate over stigma in public health can be organized around several competing ethical considerations:

Chapter 11: Synthesis and Open Questions

11.1 Recurring Themes

Several themes recur across the topics covered in this course:

1. The tension between autonomy and welfare. Liberal political philosophy prizes individual autonomy, yet addiction appears to compromise the very capacity for autonomous choice. How should policy navigate between respecting liberty and protecting vulnerable individuals?

2. The role of structural injustice. Drug policy cannot be evaluated in isolation from the social structures – racism, poverty, inequality – in which it operates. Policies that appear neutral may produce deeply unjust outcomes.

3. The limits of medicalization. Framing addiction as a brain disease has both benefits (reducing moral stigma, promoting treatment) and costs (ignoring social determinants, reinforcing reductionism). No single model captures the full complexity of addiction.

4. The importance of philosophical analysis for policy. Empirical evidence alone cannot settle normative questions about drug policy. Philosophical analysis is needed to clarify concepts (paternalism, autonomy, responsibility), evaluate arguments, and articulate the values at stake.

11.2 Open Questions

The following questions remain contested and are ripe for further philosophical investigation:

• Under what conditions, if any, is paternalistic drug regulation justified in a liberal democratic state?
• Can harm reduction be fully justified without appealing to consequentialist reasoning?
• What is the proper scope of criminal responsibility for people with severe addictions?
• How should research ethics protocols account for the decision-making capacity of people with addictions?
• Is the brain disease model of addiction reformable, or should it be replaced?
• What does racially just drug policy look like in practice, not just in principle?